Meeting Banner
Abstract #4151

Pre-Clinical Evaluation of Anti-Angiogenic Agent RO0281501 on R3327 at Prostate Model Using Lactate MRS and DCE-MRI

Jadegoud Yaligar1, Sunitha B. Thakur1,2, Mihai Coman1, Mihaela E. Lupu1, Ya Wang1, Kenneth Kolinsky3, Brian Higgins3, Kristen L. Zakian1,2, Jason A. Koutcher1,4

1Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, USA; 2Radiology, Memorial Sloan-Kettering Cancer Center; 3Discovery Oncology, Hoffmann-La Roche, Nutley, NJ, USA; 4Medicine, Memorial Sloan-Kettering Cancer Center

Angiogenesis is critically mediated by endothelial cell receptor tyrosine kinase. Present study designed to study the anti-angiogenic effect of RO0281501 in R3327 AT rat prostate tumor model by MRS tumor lactate measurement and DCE-MRI. Post 24hr treatment tumor inhibition was 18 % and by day 7 it was 40 % (compared to control group). Treated group Akep (tumor rim) value at 24hrs is significantly (p<0.05) lesser than its baseline Akep value whereas reduction in Akep is not signficant in control group. Lactate detected prior to treatment has significantly (p<0.05) reduced after 24hr of treatment and increased significantly on day 7.